NASDAQ · QTTB
Q32 Bio Inc.
$8.71-$0.16 (-1.8%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.26% below the high.
Loading market information…
NASDAQ · UBX · USD
Stock price, earnings
Quote as of Sep 4, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Unity Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.55% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Unity Biotechnology, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Unity Biotechnology, Inc. is a biotechnology firm specializing in the development of therapeutic solutions aimed at slowing, halting, or even reversing age-associated diseases. Leading its pipeline, the drug candidate UBX1325 is currently undergoing Phase II clinical trials to treat age-related vision disorders, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. Additionally, the company is advancing UBX1967 for various ophthalmologic conditions, while UBX2050, a human anti-Tie2 agonist monoclonal antibody, also targets age-related eye diseases. Furthermore, UBX2089, an a-Klotho hormone drug candidate, is in development for numerous neurological indications. Established in 2009 as Forge, Inc., the company adopted the name Unity Biotechnology, Inc. in January 2015 and is headquartered in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:00 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Nov 13, 2023 |
| -$0.66+24.14% vs estimate |
| $0.00 |
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.71-$0.16 (-1.8%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.26% below the high.
$1.08+$0.07 (+6.93%)
Lisata Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.7% below the high.
$0.03-$0.02 (-31.78%)
Gritstone bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.98% below the high.
$0.09-$0.00 (-1.32%)
Atreca, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.5% below the high.
$3.45+$0.07 (+2.07%)
AzurRx BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 5.74% below the high.
$0.00$0.00 (0.0%)
RVL Pharmaceuticals plc’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
$0.04-$0.01 (-13.39%)
Aravive, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.37% below the high.
$0.15-$0.01 (-6.66%)
VivoSim Labs, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.67% below the high.
